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Tricuspid atresia (TA) is a complex congenital heart disease that presents with cy-
anosis in the neonatal period. It is invariably fatal if left untreated and requires
multiple stages of palliation. Early recognition and timely surgical intervention are
therefore pivotal in the management of these infants. This literature review con-
siders the pathophysiology, presentation, investigations, and classification of TA.
Moreover, it discusses the evidence upon which the latest medical and surgical
treatments are based, as well as numerous recent case reports. Further work is
needed to elucidate the etiology of TA, clarify the role of pharmacotherapy, and
optimize the surgical management that these patients receive.
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1 | INTRODUCTION
Tricuspid atresia (TA) is a cyanotic congenital heart disease
(CHD) characterized by total agenesis of the tricuspid valve. It
accounts for approximately 1% of all cases of CHD and its in-
cidence, which is similar in both males and females,1 is reported
as ~0.1 per 1000 individuals.2 This places it as the fourth most
common cyanotic CHD after tetralogy of Fallot, transposition of
the great arteries (TGA), and hypoplastic left heart syndrome.2
Risk factors for TA include Down syndrome, poorly controlled
diabetes, excess alcohol consumption during pregnancy, and a
family history of CHD.3
TA is associated with high mortality without early interven-
tion.4 It is, therefore, important to recognize its presentations,
order the relevant investigations, and initiate swift surgical
management. This review discusses the pathogenesis, presenta-
tion, workup and management of patients with TA. In particular,
the different surgical options and intraoperative techniques are
described in detail.
2 | PATHOGENESIS
Although the underlying etiology of TA is poorly understood, it is
known to arise due to a disruption of tricuspid valvulogenesis.5
Physiological atrioventricular (AV) valvulogenesis is a multistep
process involving the Wnt/β‐catenin, bone morphogenetic protein/
transforming growth factor‐β, and Ras/extracellular‐signal‐regulated
kinase (ERK) pathways.6 Genetic mutations in these pathways have
been proposed to underline certain cases of TA, such as a germline
homozygous missense mutation in RASA1, which encodes a protein
that regulates the Ras/ERK cascade.5 Compound heterozygous mis-
sense mutations in the NFATC1 gene, whose protein acts further
downstream in the Ras/ERK pathway, have also been reported.7 The
familial recurrence of TA is thought to be extremely low,8 although
an autosomal recessive pattern of inheritance has been described in
some cases.9 Further research is required to elucidate the complex
genetic control of valvulogenesis and how this is dysregulated in TA.
To best understand how these patients present, it is necessary
to briefly describe the most common route of blood flow through a
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heart with TA (Figure 1). In TA, the right atrium is separated from
the hypoplastic right ventricle. This means that a patent foramen
ovale or atrial septal defect (ASD) is required to enable deox-
ygenated blood from the systemic venous circulation to mix with
oxygenated blood returning from the lungs.10 Usually, this occurs in
the left atrium, and the resultant partially oxygenated blood is then
pumped out of the aorta by the left ventricle. To reach the right‐
sided outflow tract, this partially oxygenated blood can be shunted
from left‐to‐right across a ventricular septal defect (VSD). It then
leaves through the pulmonary trunk, which may or may not be
stenosed at its entrance, or entirely hypoplastic. In some cases
where a VSD is not present or there is significant pulmonary ob-
struction, the patient is reliant on a patent ductus arteriosus (PDA)
to enable blood flow into the pulmonary circulation. While the
cardiac output is mixed in TA, it may still provide sufficient oxy-
genation to minimize cyanosis if it contains a great enough pro-
portion of oxygenated pulmonary venous return. The degree of
pulmonary blood flow (PBF) is, therefore, the main determinant of
cyanosis in these infants. This, in itself, is determined by the extent
of pulmonary obstruction, the existence and size of a VSD, the re-
lationship of the great arteries, and the presence of a PDA.11
3 | PRESENTATION
Around 50% of individuals with TA present with symptoms on the
first day of life, with 80% being symptomatic by the first month.4
Generally, two distinct presentations are observed. The first group of
patients have high PBF due to left‐to‐right shunting across a VSD, a
lack of pulmonary obstruction, and if present, TGA. They present
with minimal cyanosis initially but go on to develop right‐heart strain
and cardiac failure in the first few weeks of neonatal life.4 Patients
typically exhibit fatigue, difficulties in feeding, failure to thrive, and
recurrent respiratory tract infections. On examination, one may find
tachypnea, tachycardia, hepatomegaly, and prominent neck venous
pulsations. Splitting of the S2 heart sound and an S3 at the cardiac
apex may also be heard, in addition to a variety of murmurs as de-
scribed below.11 Coarctation of the aorta commonly occurs in this
subset of patients and may predispose to early heart failure.4 In these
cases, decreased femoral pulses may also be palpated.11
The second group of patients consists of those with reduced PBF
and accounts for the majority of infants with TA.12 This is usually due
to pulmonary obstruction and/or a small or absent VSD.4 These pa-
tients exhibit central cyanosis, tachypnoea and hyperpnoea within the
first few days of life.4 Clinically, their condition may be exacerbated by
the closure of the ductus arteriosus, as this is an important means by
which these infants get blood flow to their lungs. On examination,
patients may have an attenuated right ventricular impulse and an “a”
wave in their jugular venous pressure; however, no hepatomegaly or
clinical signs of heart failure are observed at this stage.4
In both groups, murmurs are usually heard on auscultation of the
precordium. At the lower left sternal border, a holosystolic murmur is
often appreciated. This represents the underlying VSD and its intensity is
inversely related to its size. For this reason, this murmur may not be
heard in patients with a large VSD. At the pulmonic position, a continuous
“machinery”murmur signifies a PDA, and at the upper left sternal border,
infants with pulmonary stenosis may also have a systolic ejection
murmur.11 Careful and precise auscultation is, therefore, required to
differentiate the mix of sounds that may be heard on examination.
4 | INVESTIGATIONS
Advancements in antenatal cardiac screening have resulted in as many
as 67% of TA cases being diagnosed before birth inWales (UK), though
this may be up to 100% in other countries such as Italy.13 However, in
some places without national screening policies and limited health care
resources, this figure may be comparatively lower.13 The National
F IGURE 1 Blood flow in tricuspid atresia.
A, Normal. B, TA. *Patent foramen ovale or
ASD. ASD, atrial septal defect; TA, tricuspid
atresia
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Health Service in the UK offers a routine fetal ultrasound scan be-
tween 18 and 22 weeks of gestation to detect congenital abnormal-
ities.14 If this is suggestive of CHD, a fetal echocardiogram can be used
for subsequent diagnosis.14 Antenatal diagnosis of CHD has been in-
strumental in reducing the mortality rates from cardiac compromise
before scheduled neonatal cardiac surgery.15
If the TA is not identified during antenatal screening, it may be
diagnosed shortly after birth. In the UK, newborns are routinely ex-
amined within 72 hours of birth for signs such as cyanosis and cardiac
murmurs.14 This involves pulse oximetry, which estimates systemic ar-
terial oxygen saturations and provides a rapid, highly specific and
moderately sensitive method of detecting critical CHDs, even in
asymptomatic newborns.16 Cyanotic CHD can also be distinguished from
respiratory causes of cyanosis using high‐flow oxygen. In addition, ar-
terial blood gas analysis can provide information regarding ventilatory
and metabolic status. This is particularly important in patients that
present with severe disease, as it may identify hypercapnia and acidosis.4
A full blood count, including hematocrit and hemoglobin, is also required
to check for long‐standing hypoxaemia.17
In TA, an electrocardiogram (ECG) typically shows left axis
deviation in the frontal plane.12 This is less commonly seen in TA
patients with accompanying TGA.12 There may also be tall and
peaked P waves in lead II and the right chest leads (due to right atrial
enlargement), increased amplitude of S waves in leads V1‐2 and R
waves in leads V5‐6 (due to left ventricular hypertrophy), and de-
creased R waves in leads V1‐2 and S waves in leads V5‐6 (due to
diminished right ventricular forces).4 While these ECG features may
not always be present, when they are identified in a patient with
cyanotic CHD, they are virtually diagnostic of TA.4
Chest radiographs are routinely used in the workup of CHD. In
TA, radiography can be used to categorize patients into groups of
high or low PBF. Those with pulmonary oligemia often show a
normal‐sized heart, increased concavity in the region of the pul-
monary artery segment, and a prominent right atrial shadow.12
Conversely, those with increased PBF show cardiomegaly and pro-
minent pulmonary vasculature.12 Crucially, the distinction between
increased and decreased pulmonary vasculature markings on chest
radiographs, in addition to history‐taking, physical examination and
ECG, may be sufficient to diagnose TA.12
Generally, the definitive test in CHD diagnosis is echocardiography,17
though the aforementioned investigations may be sufficient in some
cases of TA. Two‐dimensional echocardiography classically shows en-
largements of the atria and left ventricle, a hypoplastic right ventricle, an
atretic tricuspid valve, as well as ASDs, VSDs, and occasionally, TGA and/
or aortic coarctation.12 Doppler echocardiography can reveal shunting
across septal defects and the presence of an obstructive pulmonary
outflow tract, in addition to estimating pulmonary artery pressures.12
5 | CLASSIFICATION
Multiple classification systems have been described for TA based on
valve morphology,18 the radiographic appearance of pulmonary
vascular markings,19 and the great‐artery relationships.20 However,
due to a lack of consistency between methods, a unified classification
system was later proposed (Figure 2).22 While the principle grouping is
still based on the interrelationships of the great arteries, all categories
are further subdivided according to the presence of other cardiac de-
fects. Specifically, type III TA describes great‐artery abnormalities
other than dextro‐TGA, including levo‐TGA (L‐TGA, subtype 1), double
outlet right ventricle (subtype 2), double outlet left ventricle (subtype
3), anatomically corrected dextro‐malposition of the great arteries
(subtype 4), and anatomically corrected levo‐malposition of the great
arteries (subtype 5). In addition, all main types and subtypes can be
described as “a,” “b,” or “c,” referring to pulmonary atresia, pulmonary
stenosis (or hypoplasia), or no pulmonary stenosis, respectively. Fol-
lowing this, the integrity of the ventricular septum is considered and
other malformations may be described.22 An example could therefore
be written as type Ia TA with a large VSD.
6 | MANAGEMENT
6.1 | Initial management
Patients with TA require multiple cardiac surgeries to maximize long-
evity. These take a significant amount of time and resources to organize.
Prostaglandin E1 (PGE1) can therefore be given in the meantime to
maintain a PDA.23 This is a potentially life‐saving intervention in cases
of TA with reduced PBF, as these infants rely on a PDA for the pul-
monary and systemic circulations to mix.24 Without prostaglandins, the
ductus arteriosus typically closes within 2 to 3 days of birth, leading to a
worsening of symptoms. However, a recent systematic review published
by the Cochrane Database has highlighted the lack of randomized
controlled trials (RCTs) focusing on the safety and efficacy of PGE1 in
neonates with ductal‐dependent cardiac lesions.24 In addition, the use of
PGE1 in newborns has been associated with numerous adverse effects,
such as fever (which could delay surgical management),25 hypokalemia,
hypotension,26 apnea, and gastric outlet syndrome.23 However, many of
these side effects are manageable and should not deter clinicians from
using PGE1 in newborns with CHD.23
In cases of TA with reduced PBF and cyanosis, patients may also
undergo surgery to have a polytetrafluoroethylene conduit fitted
between the right subclavian artery and right pulmonary artery.27
This is known as a modified Blalock‐Thomas‐Taussig shunt (MBTS)
and like PGE1, it also enables temporary mixing of the systemic and
pulmonary circulations. The MBTS shunt differs from its predecessor,
the original Blalock‐Taussig shunt, as it uses a synthetic connection
rather than a direct anastomosis between arteries.28 Although the
MBTS is commonly used in the treatment of CHD and has been
validated in TA, it is associated with high in‐hospital mortality,
especially in patients less than 3 kg.29 Reports of refractory cardiac
arrest following shunt insertion have even been described.27 Ductal
stenting is a reasonable alternative to the MBTS, as it is associated
with similar or improved pulmonary artery growth, fewer complica-
tions, a shorter length of stay, and improved survival.30
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Conversely, patients with TA and high PBF may benefit from
pulmonary artery banding (PAB) to reduce blood flow to the
lungs.31 This may help us to prevent pulmonary plethora,
right‐heart strain, and subsequent cardiac failure. Initially, this
was carried out using a Gore‐Tex (non‐stretchable) band.
However, as the circulation underwent rapid and unpredictable
growth, this often became too tight before the intended removal
surgery.32 Dilatable alternatives have therefore been devel-
oped.32 Absorbable pulmonary bands have also been described in
the literature, with one case reporting complete absorption
within 5 months.33 By this time, the patient's VSD had narrowed,
therefore sustaining this reduction in PBF and avoiding a second
operation or the need for pulmonary arterioplasty.33 It should be
noted, however, that variable rates of resorption may result in
unpredictable PBF.34 This may make preparations for definitive
management less adequate. Similarly, subaortic stenosis and
subsequent aortic arch obstruction after PAB may also
complicate further procedures.31 In cases with a persistent
truncus arteriosus, either bilateral PAB,35 or unifocalization
of the pulmonary arteries and the placement of a BTS shunt can
be used.36
Another subgroup to be aware of is those suffering from both
TA and TGA. These patients commonly develop subaortic stenosis
and outflow tract obstruction, which may require VSD enlarge-
ment and resection of the subaortic conus.37 However, as this can
result in complications such as heart block, an alternative method
known as the Damus‐Kaye‐Stansel (DKS) procedure is often
used.37 This involves an end‐to‐side anastomosis between the
main pulmonary artery and ascending aorta.38 More recently, a
double‐barrel variant of the DKS procedure has emerged, in which
the main pulmonary artery and initial aortic segment lead into a
single ascending aorta.38 This technique has been shown to be
superior over its predecessor in reducing the amount of pulmonary
regurgitation before definitive management.38
F IGURE 2 Classification of tricuspid atresia.
A, TA with normal great arteries (69%). B, TA with
D‐TGA (28%). C, TA with great‐artery position
other than dextro‐transposition. L‐TGA (subtype
1) is shown (3%). D, TA with persistent truncus
arteriosus. Data from Eidmen et al.21. D‐TGA,
dextro‐transposition of the great arteries; L‐TGA,
levo‐transposition of the great arteries; TA,
tricuspid atresia
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6.2 | Definitive management
6.2.1 | Preparing for the Fontan procedure
The Fontan procedure is a method of redirecting systemic venous
blood directly into the pulmonary arteries without passing through
the right ventricle. This is a palliative procedure that bypasses the
atretic tricuspid valve. However, establishing a Fontan circulation
usually involves multiple stages of repair.
The first stage, known as the bidirectional Glenn procedure, is
carried out between 4 and 6 months of life.39 It involves the se-
paration of the superior vena cava (SVC) from the right atrium and
the formation of an end‐to‐side anastomosis between the SVC and
right pulmonary artery. The proximal pulmonary trunk is also divided
or ligated to prevent retrograde blood flow down the outflow tract.40
This arrangement allows blood to flow down the SVC and bidir-
ectionally into both lungs, hence the name of this procedure
(Figure 3A).41 This distinguishes the bidirectional Glenn from its
predecessor, the original Glenn procedure, which is based on uni-
directional flow.42 The resultant circulation bypasses the right side of
the heart, therefore reducing ventricular load, myocardial work, and
offsetting heart failure.42 The bidirectional Glenn is not without its
risks though; case studies have reported pulmonary vein stenosis and
in the context of main pulmonary artery ligation, massive aneurysm
of the right ventricular outflow tract.40,43
Another method of creating this cavopulmonary anastomosis is
the hemi‐Fontan procedure. This is similar to the bidirectional Glenn
method but the connection between the SVC and right atrium is
maintained and instead, a homograft is sewn at the SVC‐right atrium
connection, thereby reducing systemic blood flow to the right
atrium.41 Following either of these approaches, the Fontan proce-
dure can be attempted.
It should be noted though that most deaths in TA occur during
the periods between operations.27 This is increased for infants with a
low weight at the time of their first cardiac surgery.44 A greater
emphasis on identifying other risk factors for increased mortality
during this time is required to improve interstage outcomes.
6.2.2 | Performing the Fontan procedure
The final surgical step is the Fontan procedure, which completes the
Fontan circulation and allows for improved PBF. This is usually
carried out between 18 and 36 months of age.39 Completing the
Fontan circulation reduces volume overload, preserves ventricular
functioning, and reduces the degree of atrial dilatation.45,46 It is well
known that performing this surgery post‐hemi‐Fontan reduces mor-
tality rates in neonates.47
Originally, the Fontan operation involved correcting the ASD and
creating an anastomosis between the proximal end of the right pul-
monary artery and right atrial appendage. This allowed blood to flow
from the inferior vena cava (IVC) directly to the lungs via the right
atrium (Figure 3B).48 It has since been modified and there are
two common variants used in practice today. The intracardiac lateral
tunnel technique involves using a prosthetic patch to create a
channel from the IVC, through the right atrium, through the distal
part of the SVC and into the right pulmonary artery (Figure 3C).49
Another method uses an extracardiac conduit to directly connect the
IVC and the right pulmonary artery (Figure 3D).49 The outcomes of
these techniques are generally similar, with a recent systematic re-
view concluding that there are no significant differences in the short‐
term incidence of post‐Fontan arrhythmias between the lateral
tunnel and extracardiac conduit.50 However, the authors note that
the latter may be preferred and has the potential to “significantly
lower the risk of late arrhythmias after Fontan surgery”.50 It can also
minimize the need for cardiopulmonary bypass or remove it com-
pletely, which may help us to preserve ventricular and pulmonary
function.51 Khairy and Poirier49 point out that these benefits are
theoretical and remain to be proven by clinical trials.
6.2.3 | Outcomes after the Fontan procedure
Survival after the Fontan procedure for TA has been reported as 90%
at the age of 1 month, 81% at 1 year, 70% at 10 years, and 60% at
20 years.52 This is in comparison to survival rates of 74% at 1 month,
58% at 1 year, and 52% at 4 years for hypoplastic left heart
syndrome.53 However, while the Fontan procedure can help us to
extend the lives of patients with TA, it is a palliative operation and
results in a nonphysiological circulation. It is performed with the in-
tent of normalizing PBF, but in some cases, it can actually result in
increased PBF, increased pulmonary vascular resistance, and ven-
tricular dysfunction.54 A recent meta‐analysis has shown that the
overall mortality rate across all variants of the Fontan procedure is
8.3% at a mean follow‐up time of 8.9 years.55 Schwartz et al55 also
found that patients treated by the original Fontan method had sig-
nificantly higher mortality rates at this same endpoint. To reduce the
likelihood of this occurring, a fenestrated atrial baffle can be used to
alleviate the increased pulmonary pressures, especially in those with
pulmonary stenosis or abnormal pulmonary anatomy (Figure 3D).45,54
It should be noted that survival following the Fontan procedure
has improved over the last 30 years due to surgical advancements,
patient selection, and staging of the Fontan circulation.51 The aver-
age life expectancy of patients is now 35 to 40 years, although this is
still in contrast to 70 to 80 years in the general population.56 As a
result of post‐Fontan patients living longer, late complications are
becoming increasingly appreciated.57 These include protein‐losing
enteropathy,57 thromboembolism, and arrhythmias, with the latter
being a major risk factor for morbidity.51 Eventually, many of these
patients require cardiac transplantation. In fact, 70% to 80% of pa-
tients transplanted for CHDs are those with univentricular systems
such as TA.58 This results in similar long‐term survival compared to
those transplanted for other reasons.58
It is important that clinicians fully explain the outcomes of the
Fontan procedure, as this may influence the parent's decision to
consent to this operation. It has been reported that due to the
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long‐term complications associated with a Fontan circulation, some
parents prefer end‐of‐life care at a younger age.59 In their view, this
prevents the prolongation of their child's suffering, however, this
remains a highly controversial issue.59
6.3 | Postoperative management
Angiotensin‐converting enzyme inhibitors (ACEi) may also help in
managing TA by inhibiting the production of angiotensin II and its
vasoconstrictive effects, thereby decreasing systemic vascular re-
sistance (SVR). This may be especially useful in those with Fontan
circulations, as it is believed that the hemodynamic changes that
occur in these patients result in activation of the sympathetic ner-
vous system, an increased SVR, and a decreased cardiac output.60 In
line with this, ACEi improves cardiac function and reduce the de-
gree of ventricular hypertrophy in children with volume overload.61
However, there are no current guidelines for their use in func-
tionally univentricular neonates.62 Only one large‐scale double‐
blinded RCT has been performed to date focusing on the use of
ACEi in univentricular CHD.63 In this study, the authors adminis-
tered enalapril to 230 infants with single ventricle defects in the
first year of life and found no significant differences in ventricular
function or heart failure severity at 14 months.63 The use of ACEi
also extends to reducing AV valve regurgitation and pleural effu-
sions in post‐Fontan patients.62,64
Where post‐Fontan arrhythmias occur, clinicians may be temp-
ted to use antidysrhythmic medications. However, patients are often
resistant to these, and catheter ablation is associated with a lower
recurrence of atrial tachyarrhythmia.65 Early referral to a specialty
center should therefore be considered.65 Postoperative protein‐
losing enteropathy can be treated using the dietary limitation of long‐
chain triglycerides, medications including diuretics and corticoster-
oids, as well as surgical management, such as a Fontan fenestration.57
F IGURE 3 Surgical repair of tricuspid atresia.
A, Bidirectional Glenn procedure. B, Original
Fontan procedure. C, Intra‐atrial lateral tunnel
Fontan technique. D, Extracardiac conduit Fontan
technique with fenestration
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More recently, it has been shown that selective glue embolization of
leaking intestinal lymphatic trunks led to a prompt reversal of PLE.66
Third, post‐Fontan patients are at a high risk of thrombus formation.
As such, they should receive individualized thromboprophylaxis. Ac-
cording to a recent multicenter study, antiplatelet agents result in a
lower incidence of combined thromboembolic events than antic-
oagulation for this purpose.67 Other post‐Fontan complications are
reviewed elsewhere.57
6.4 | Other anatomical variants
As described above, TA can occur alongside various other cardiac
defects. Many of these are seen in day‐to‐day practice, such as VSDs
or less commonly, TGA.21 However, other rarer anatomical variants
can also occur. These are worth discussing as they often demand
nonroutine surgical management. One such variant is the presence of
an interrupted IVC in patients with TA (or other functionally
univentricular CHDs). This may occur below the level of the hepatic
veins, such that they are still able to drain into the RA. These cases
are treated via the Kawashima operation, which involves anasto-
mosing the SVC and azygos veins with the pulmonary arteries.68
Interestingly, this same procedure has been used to treat two
children with TA and bilateral SVCs.69 In this study, the authors
conclude that the Kawashima operation is a safe and effective
method of treating bilateral SVCs and enables preparation for future
total cavopulmonary shunting.69
Milovanovic et al70 report the rare occurrence of TA with an
aortopulmonary window or connection between the aorta and pul-
monary trunk. They subsequently suggest that the initial stage of
palliation should involve full separation of the aorta and pulmonary
artery using patch angioplasty.70 Following this, a systemic‐to‐
pulmonary shunt (such as the MBTS) is placed, with the aim of es-
tablishing a full Fontan circulation in the future.
7 | CONCLUSION
TA is a complex CHD that is associated with significant morbidity and
mortality. It is important that clinicians are aware of its variable
presentations, the investigations that are required in these patients,
and the multiple steps involved in surgical palliation. There is a need
for future studies focusing on the pathophysiology, interstage out-
comes, and postoperative or long‐term management of patients with
TA. This is likely to become increasingly more important as patient
longevity improves.
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